એલેમ્બિક ફાર્માસ્યુટિકલ્સ શેર કિંમત

એલેમ્બિક ફાર્માસ્યુટિકલ્સ લિમિટેડ, મેન્યુફેક્ચર્સ અને માર્કેટ ઇન્ડિયા ફોર્મ્યુલેશન્સ, ઇન્ટરનેશનલ જેનેરિકસ અને ઍક્ટિવ ફાર્માસ્યુટિકલ ઘટકો (એપીઆઈ). મજબૂત આર એન્ડ ડી ફોકસ સાથે, એલેમ્બિક ભારત અને યુએસ બજારોના નોંધપાત્ર યોગદાન સાથે આવકમાં $600 મિલિયનથી વધુ મેળવે છે.

Alembic Pharmaceuticals has an operating revenue of Rs. 6,357.26 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 10% is healthy, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -19% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 41 which is a POOR score indicating inconsistency in earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 38 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

ડિસ્ક્લેમર: આ સ્ટૉક એનાલિસિસ રિપોર્ટ માત્ર માહિતીના હેતુઓ માટે અલ્ગોરિધમ રૂપે બનાવવામાં આવે છે અને તેને ખરીદ અથવા વેચાણની ભલામણ તરીકે ગણવામાં આવશે નહીં.